Answers are grounded in this paper and cite their sources.
This review evaluates T-cell redirecting therapies and their impact on overall survival in follicular lymphoma patients, highlighting treatment challenges.
Patients with low-risk follicular lymphoma (FL) have a median overall survival (OS) exceeding 20 years. Whereas those with adverse features, such as a high Follicular Lymphoma International Prognostic Index (FLIPI) score or progression of disease within 24 months of front-line treatment (POD24) have inferior outcomes. Standardized treatment in the second line and beyond is not firmly established and largely depends on patient fitness and medication access. The duration of response decreases with each line of therapy. In this review, we evaluate the evidence for T-cell‑redirecting therapies in FL.
No takes yet. Share an insight, caveat, or question.
El-Haddad et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: